Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
Insmed (Nasdaq: INSM) reported Q2 2026 results with total revenues of $425.5M. BRINSUPRI (brensocatib) revenue was $309.2M (+49% QoQ), and ARIKAYCE (amikacin liposome) revenue was $116.3M (+8% YoY). The company raised 2026 BRINSUPRI guidance to $1.25B-$1.40B and reiterated ARIKAYCE guidance of $450M-$470M, with peak sales for lead programs now above $14B.
How this was made
The 30-second read
Why it matters
The primary tradable catalyst is the raised 2026 BRINSUPRI revenue guidance range, supported by reported Q2 BRINSUPRI growth. Secondary catalysts include Japan regulatory decision timing for brensocatib and potential ARIKAYCE label expansion via U.S. sNDA review and Japan PMDA discussions.
Market read
This is a guidance-and-results update with a clear upward revision for BRINSUPRI, likely driving near-term estimate changes and sentiment for INSM.
What to watch
SG&A and R&D rose sharply in Q2 2026; margin and cash burn trajectory could temper the stock reaction even with higher BRINSUPRI guidance.
Background
Insmed is a commercial-stage biopharma focused on respiratory therapies (BRINSUPRI, ARIKAYCE) and TPIP for pulmonary hypertension indications, with additional early-stage pipeline programs.
Ticker impact
Insmed reported Q2 2026 results and raised 2026 BRINSUPRI revenue guidance to $1.25B to $1.40B from at least $1B.
Bullish bias for INSM as traders reprice 2026 BRINSUPRI revenue expectations; follow-through depends on Japan regulatory timing and ARIKAYCE label-expansion progress.
The article discloses a specific, time-bound guidance increase plus Q2 product revenue growth, which typically drives immediate estimate revisions. Other pipeline items are supportive but less quantifiable than the BRINSUPRI guidance range.
Market effects
Reinforces investor appetite for commercial-stage respiratory biopharma with near-term label and regulatory catalysts.
Japan regulatory decision timing for brensocatib could affect expectations for future international revenue contributions.
Could modestly influence sentiment around inhaled respiratory drug franchises if peers face similar bronchiectasis and MAC market dynamics.
Counterpoint
Raised peak revenue estimates may outpace execution risk if Japan regulatory timing or international launch policy changes delay incremental revenue.
Key entities
- companyInsmed Incorporated
Reported Q2 2026 financial results and updated 2026 revenue guidance for BRINSUPRI and ARIKAYCE, plus business milestones across TPIP and pipeline programs.
- productBRINSUPRI (brensocatib)
Commercial respiratory therapy; Q2 2026 revenue grew 49% QoQ and 2026 revenue guidance was raised to $1.25B to $1.40B.
- productARIKAYCE (amikacin liposome inhalation suspension)
Commercial respiratory therapy; Q2 2026 revenue grew 8% YoY and 2026 guidance was reiterated at $450M to $470M.
- productTPIP (treprostinil palmitil inhalation powder)
Phase 3 program in PAH and PH-ILD; company reported positive 12-month OLE data and outlined upcoming Phase 3 starts.
- regulatorFDA
Received an ARIKAYCE sNDA for newly diagnosed MAC patients, per the company update.
